This article is more than 5 years old. Information may no longer be current.
Bausch & Lomb acquires assets of Italian ophthalmic pharmaceuticals company
ROCHESTER, N.Y. — Bausch & Lomb has acquired the commercial assets of Tubilux Pharma, a privately owned Italian company, according to a press release from Bausch & Lomb.
Tubilux creates and sells proprietary, over-the-counter and branded generic products in Italy and distributes in nearly 30 other countries, the release said. Bausch & Lomb has obtained the company's portfolio, commercial operations and sales operations.
The company's portfolio includes dry eye products Oxyal, Lipimix and Vitadrop; glaucoma products Cebrolux and Timolux; an anti-infective product, Oftaquix; and an anti-inflammatory product, Fluaton.
Group Tubilux will continue to manufacture products for Bausch & Lomb in a multi-year contract, according to the release.
Charl van Zyl, head of Bausch & Lomb's pharmaceuticals business for Europe, Middle East and Africa, said the acquisition will more than double the company's holdings in the Italian ophthalmic pharmaceuticals market.
The acquisition's financial terms will not be made public.